Dr. Brad McGregor

I mean, I'm really excited that I think EVP in the perioperative setting is going to cure patients and limit the need for therapy in the metastatic setting.

And so I think all these questions had about what do you do post-EVPembroke, they progress in the metastatic setting, long-term toxicities, you know, with a defined course at EVPembroke where you can cure more patients.

I think that's going to be amazing.

I think as we look forward to the future, I think, you know, using CTNA to help guide therapy, help make therapy decisions, and then novel approaches combining with ED Pembro or novel ACs with platinum, like in the refractory setting.

I think, you know, after like 30 years of negative trials, it's like a positive plenary every year for bladder cancer.

So I think...

We're in a very exciting time as we're really making leaps and bounds in how we treat our patients.

Thanks.

It's been a great discussing this data.

Administrative support provided by Judy De La Cruz.